First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
Peng Ye, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan
Topics & Concepts
AtezolizumabMedicineOncologyInternal medicineCancerImmunotherapyPembrolizumabCancer Immunotherapy and BiomarkersEconomic and Financial Impacts of CancerLung Cancer Treatments and Mutations